Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Latest Company News

Oct 22, 2026, 08:53 UTC
Asymchem Laboratories reported third-quarter and first-nine-month 2026 revenue of 1.788 billion yuan and 5.395 billion yuan, attributable net profit of 332 million yuan and 852 million yuan, and adjusted net profit of 203 million yuan and 728 million yuan.
Source:
Sep 30, 2026, 09:47 UTC
On the last trading day before China's National Day holiday, Chinese pharmaceutical stocks surged broadly, with the pharma index closing up 2.73% and the innovative drug index up 3.42%, while semiconductors fell 2.75%.
Source:
- finance.ifeng.com
Sep 30, 2026, 00:50 UTC
Yinhang Biology announced on September 30 that it completed a 450 million yuan Pre-IPO financing round, with existing shareholders Oriza Holdings, Hunan Caixin and Hunan Caixin increasing their investment, and new investors including Suzhou Venture Capital, Suzhou Industrial Investment, Yuanfeng Capital and Chuangke Zhisheng joining.
Source:
- finance.sina.cn
Sep 28, 2026, 10:01 UTC
Kailaiying plans to amend its articles of association to increase registered capital from 361 million yuan to 362 million yuan and total shares from 360,663,470 to 361,948,670 after registering 2,436,500 restricted shares under its 2026 A-share incentive plan.
Source:
- finance.sina.cn
Aug 24, 2026, 10:29 UTC
Asymchem Laboratories announced its first-half 2026 results: revenue of 3.607 billion yuan, up 13.13% year-on-year, and net profit attributable to shareholders of 520 million yuan, down 15.71% from 617 million yuan in the same period of 2025.
Source:
- finance.sina.cn
- aastocks.com
Aug 7, 2026, 23:56 UTC
Chinese innovative drug and CXO stocks rebounded strongly, with the CSI Innovative Drug Industry Index rising 28.04% since June 9, 2026, and several stocks hitting daily limits on August 7, 2026.
Source:
- m.21jingji.com
Jul 30, 2026, 10:57 UTC
Asiachem plans to inject 1.2397 billion yuan into its controlled subsidiary Asiachem BIO via a capital increase, raising its stake from 83% to 83.5%.
Source:
- finance.sina.cn
Jul 16, 2026, 09:25 UTC
Citigroup reduced its long-term holding of Asymchem (Tianjin) H-shares on July 10, with the stake dropping from 5.09% to 2.92%.

002821.SZ

Asymchem Laboratories reported third-quarter and first-nine-month 2026 revenue of 1.788 billion yuan and 5.395 billion yuan, attributable net profit of 332 million yuan and 852 million yuan, and adjusted net profit of 203 million yuan and 728 million yuan.

On the last trading day before China's National Day holiday, Chinese pharmaceutical stocks surged broadly, with the pharma index closing up 2.73% and the innovative drug index up 3.42%, while semiconductors fell 2.75%.

Kailaiying plans to amend its articles of association to increase registered capital from 361 million yuan to 362 million yuan and total shares from 360,663,470 to 361,948,670 after registering 2,436,500 restricted shares under its 2026 A-share incentive plan.

Asymchem Laboratories announced its first-half 2026 results: revenue of 3.607 billion yuan, up 13.13% year-on-year, and net profit attributable to shareholders of 520 million yuan, down 15.71% from 617 million yuan in the same period of 2025.

Chinese innovative drug and CXO stocks rebounded strongly, with the CSI Innovative Drug Industry Index rising 28.04% since June 9, 2026, and several stocks hitting daily limits on August 7, 2026.

Asiachem plans to inject 1.2397 billion yuan into its controlled subsidiary Asiachem BIO via a capital increase, raising its stake from 83% to 83.5%.

Citigroup reduced its long-term holding of Asymchem (Tianjin) H-shares on July 10, with the stake dropping from 5.09% to 2.92%.